AUTHORS
Patrick Gould, MD, Alok Deshane, MD, MA2, Alexandra Dreyfuss, MD, MSTR3, Andriy Derkach, PhD4, Kylee Maclachlan, MD, PhD5, Malin Hultcrantz, MD PhD6, Hani Hassoun, MD7, Sham Mailankody, MBBS8, Urvi A. Shah, MD, MS, DipABLM9, Sridevi Rajeeve, MD10, Hamza Hashmi, M.D.11, Ross Firestone, MD/PhD12, Eric Matthew Jurgens, MD13, Maximilian Merz, MD14, Francesco Maura, MD15, Gunjan L. Shah, MD, MS16, Michael Scordo, MD17, Heather J. Landau, MD18, Sergio Giralt, MD19, Gustav Cederquist, MD, PhD20, Zachary Moore, MD, PhD21, Neha Korde, MD22, Alexander M. Lesokhin, MD23, Saad Z. Usmani, MD24, Joachim Yahalom, MD25, Brandon S. Imber, MD, MA26, Carlyn Rose Tan, MD27
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 University of Miami, Miami, Florida, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York, New York, United States
25 Memorial Sloan Kettering Cancer Center, New York, New York, United States
26 Memorial Sloan Kettering Cancer Center, New York, New York, United States
27 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Introduction
There is limited data on the use of radiation therapy (RT) in combination with T-cell engaging bispecific antibodies (BsAbs) for relapsed/refractory multiple myeloma (RRMM). We present safety and outcomes of patients who received RT while on BsAbs from our center.
Methods
This is a single-center retrospective study of patients with RRMM treated with BsAbs from 11/2022 to 6/2025. Patients were categorized based on timing of RT relative to BsAb initiation: 30 days prior to BsAb initiation (PreB-RT) or during BsAb treatment (concurrent RT, CRT). High-risk cytogenetics were defined as 1q+, t(4;14), t(14;16), t(14;20), and/or del(17p). Laboratory values were collected from the time of BsAb initiation to end of treatment or data cutoff (6/2025). Cytopenias were assessed using CTCAE v6.0. Progression-free survival (PFS, based on IMWG criteria) and rates of cytopenias were compared to patients who received BsAb without RT.
Results
253 patients with RRMM treated with BsAbs, including 154 (61%) on teclistamab (tec), 22 (8.7%) on elranatamab (elra), and 77 (30%) on talquetamab (talq), were identified. Baseline characteristics included median age of 70 (IQR 63-77), high-risk cytogenetics in 187/240 (78%), extramedullary disease (EMD) in 82/211 (39%), paramedullary disease (PMD) in 64/211 (30%), median of 5 (IQR 4-8) prior lines of therapy (LOT), and 42% with prior BCMA-directed therapy.
Among these 253 patients, we identified 30 who received RT within the defined intervals: 12 PreB-RT and 18 CRT (including 4 during step-up dosing). 5 patients received RT to multiple sites concurrently. Among these 30, 18 (60%) received tec and 12 (40%) talq. Baseline characteristics included median age of 66 (IQR 62-73), high-risk cytogenetics in 21/28 (75%), EMD in 14/29 (48%), PMD in 15/29 (52%), prior BCMA-directed therapy in 16/30 (53%), and median prior LOT of 6 (IQR 4-8). Sites of RT included skeletal lesions in 11/30 (37%), EMD in 7/30 (23%), and PMD in 15/30 (50%). Median dose was 20 Gy (range, 12-36), delivered in median 5 (range, 3-12) fractions. Primary indications for RT included palliation only in 22/30 (73%), oligoprogression in 5/30 (17%), bridging in 2/30 (7%), and post-operative in 1/30 (3%). In the PreB-RT group, RT occurred at a median of 12 (range, 2-28) days prior to BsAb initiation. In the CRT group, RT occurred at a median of 29 (range, 0-663) days after BsAb initiation, and BsAb therapy continued after RT for a median of 105 (range, 7-449) days. All RT for oligoprogression occurred in the CRT group, and BsAb therapy continued for a median of 85 (range, 40-449) days after RT.
The rate of G≥3 lymphopenia at BsAb initiation was significantly higher in the PreB-RT group (n=12) compared to the no-PreB-RT group (n=241) (42% vs 33%, p=0.025). There were no statistically significant differences in rates of G≥3 neutropenia (0% vs 0%, p=0.7), anemia (25% vs 26%, p=0.2), or thrombocytopenia (25% vs 14.8%, p=0.6) at baseline. Additionally, there was no significant difference in time to G≥3 neutropenia following initiation of BsAb between the PreB-RT and the no-PreB-RT groups (30-day post-BsAb initiation estimated incidence of G≥3 neutropenia, 0% vs 12% [95%CI 8.2%-16%]; HR 0.67 [95%CI 0.17-2.63], p=0.6). Among patients without G≥3 thrombocytopenia at baseline, there was no significant difference in time to G≥3 thrombocytopenia (30-day post-BsAb initiation estimated incidence of G≥3 thrombocytopenia, 11% [95%CI 0.45%-41%] vs 12% [95%CI 8.3%-17%]; HR 0.62 [95%CI 0.09-4.46], p=0.6).
In a time-to-event analysis, there was no significant difference in time to G≥3 neutropenia in the CRT group (n=18) as compared to the no-CRT group (n=235, including 12 patients in the PreB-RT group) (HR 2.60 [95%CI 0.80-8.43], p=0.2). Among patients without G≥3 thrombocytopenia at baseline, there was similarly no significant difference in time to G≥3 thrombocytopenia in the CRT group as compared to the no-CRT group (HR 2.96 [95%CI 0.68-12.8], p=0.2).
There was no difference in PFS between the PreB-RT group and the no-PreB-RT group: median PFS 4.67 vs 6.77 months (HR 1.46, 95%CI 0.74-2.89, p=0.3).
Conclusion
Our data demonstrates feasibility of integrating RT with BsAb therapy for RRMM, either prior to initiation of the BsAb or concurrently. We found no association between RT given prior to or concurrently with BsAb therapy and rates of clinically significant neutropenia or thrombocytopenia, but this should be confirmed in larger studies.
DISCLOSURES
Patrick Gould, MD: No relevant conflicts of interest to declare.